Tim is CEO and member of the Board of Directors of AgomAb. Prior to that, Tim held the position of VP Corporate Development at AM-Pharma where he and the team executed a Phase IIb trial in patients with sepsis-associated acute kidney injury, secured a $600M option-to-buy deal with Pfizer and raised $133M in a private financing round. Prior to AM-Pharma, Tim was a Senior Associate at Aescap Venture, a VC fund investing in European medical companies. Tim is a Henri Termeer Fellow and holds an executive MBA from IMD, where he was named Valedictorian. He earned a Science and Innovation Masters and a Drug Innovation Masters from Utrecht University.
Sign up to view 13 direct reports
Get started